| dbo:abstract |
Paclitaxel trevatide (development codes NG1005 and GRN1005) is an experimental chemotherapy drug that is under development by Angiochem Inc, a Canadian biotech company. Phase II clinical trials have completed for several indications, and the company is preparing for phase III trials. Paclitaxel trevatide is a paclitaxel-Angiopep-2 conjugate. Various Angiopep vectors have been composed and differ by their anti-cancer moieties. This has then been shown to be a prospective cancer therapy drug that can not only be conjugated to paclitaxel but also peptides, monoclonal antibodies, siRNA and many other biological materials. Paclitaxel trevatide has the potential to treat a variety of CNS diseases including glioma. Research has shown reduction in tumor growth in mice and rats with glioblastoma. (en) |
| dbo:casNumber |
1075214-55-9 |
| dbo:drugbank |
DB06171 |
| dbo:fdaUniiCode |
8P77G99D3P |
| dbo:thumbnail |
wiki-commons:Special:FilePath/ANG1005.png?width=300 |
| dbo:wikiPageExternalLink |
http://www.eurekalert.org/pub_releases/2008-10/hp-aad102108.php http://www.medicalnewstoday.com/articles/167848.php |
| dbo:wikiPageID |
20426260 (xsd:integer) |
| dbo:wikiPageLength |
15543 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1058711866 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:Capillaries dbr:Blood_brain_barrier dbr:Tumors dbr:Esterase dbr:Glioblastoma dbr:Glioma dbc:Experimental_cancer_drugs dbr:Apoptosis dbr:G0_phase dbr:Lipoprotein_receptor-related_protein dbr:American_Society_of_Clinical_Oncology dbr:Paclitaxel dbr:Carboxylic_acid dbr:Cell_proliferation dbr:Central_nervous_system dbr:Hydrolysis dbr:ABCC1 dbc:Taxanes dbr:Microtubule dbr:P-glycoprotein dbr:Mitotic_checkpoint dbr:File:ANG1005mechanism.pdf |
| dbp:c |
257 (xsd:integer) |
| dbp:casNumber |
1075214 (xsd:integer) |
| dbp:chemspiderid |
35003422 (xsd:integer) |
| dbp:drugbank |
DB06171 (en) |
| dbp:h |
308 (xsd:integer) |
| dbp:legalStatus |
Investigational (en) |
| dbp:n |
32 (xsd:integer) |
| dbp:o |
79 (xsd:integer) |
| dbp:smiles |
CC1=C2[C@@H]OCC (en) |
| dbp:stdinchi |
1 (xsd:integer) |
| dbp:stdinchikey |
GBVKRUOMSUTVPW-KARLVTCBSA-N (en) |
| dbp:synonyms |
NG1005; GRN1005 (en) |
| dbp:unii |
8 (xsd:integer) |
| dbp:wikiPageUsesTemplate |
dbt:Cite_journal dbt:Cite_news dbt:Infobox_drug dbt:Orphan dbt:Reflist dbt:Cite_press_release |
| dcterms:subject |
dbc:Experimental_cancer_drugs dbc:Taxanes |
| rdf:type |
owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug |
| rdfs:comment |
Paclitaxel trevatide (development codes NG1005 and GRN1005) is an experimental chemotherapy drug that is under development by Angiochem Inc, a Canadian biotech company. Phase II clinical trials have completed for several indications, and the company is preparing for phase III trials. (en) |
| rdfs:label |
Paclitaxel trevatide (en) |
| owl:sameAs |
wikidata:Paclitaxel trevatide https://global.dbpedia.org/id/4KAzz |
| prov:wasDerivedFrom |
wikipedia-en:Paclitaxel_trevatide?oldid=1058711866&ns=0 |
| foaf:depiction |
wiki-commons:Special:FilePath/ANG1005.png |
| foaf:isPrimaryTopicOf |
wikipedia-en:Paclitaxel_trevatide |
| is dbo:wikiPageRedirects of |
dbr:C257H308N32O79 dbr:ANG1005 |
| is dbo:wikiPageWikiLink of |
dbr:C257H308N32O79 dbr:ANG1005 |
| is foaf:primaryTopic of |
wikipedia-en:Paclitaxel_trevatide |
